Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab Rechallenge + Irinotecan in mCRC (REGAIN)
NCT02316496Phase 2Terminated
- Sponsor
- GERCOR
- Start
- Sep 2015
- Primary completion
- Jan 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of KL-140 in metastatic colorectal cancer (mCRC), sponsored by GERCOR. Primary endpoint: Objective Response Rate at 2 months. Started Sep 2015; status: terminated.
02
Drugs
KL-140
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02316496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02316496.